DNX-4000

DNX-4000 is a small molecule inhibitor of Janus kinase 3 (JAK3) currently in Phase 2 clinical development by Dynamix Pharmaceuticals (DynamX). The drug is being investigated for the treatment of autoimmune disorders and hematological malignancies, including various forms of cancer. JAK3 is a non-receptor tyrosine kinase that plays a critical role in the signaling pathways of cytokines that utilize the common gamma chain (γc) receptor subunit, such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. These cytokines are essential for the development, activation, and proliferation of T-lymphocytes and natural killer (NK) cells. By selectively inhibiting JAK3, DNX-4000 aims to modulate aberrant immune responses in autoimmune conditions and suppress the growth of malignant cells in hematological cancers.